Innovent Biologics, Inc. (HKG:1801)
80.25
-2.00 (-2.43%)
Jul 10, 2025, 4:08 PM HKT
Innovent Biologics Employees
Innovent Biologics had 5,659 employees as of December 31, 2024. The number of employees increased by 787 or 16.15% compared to the previous year.
Employees
5,659
Change (1Y)
787
Growth (1Y)
16.15%
Revenue / Employee
1.77M HKD
Profits / Employee
-17.80K HKD
Market Cap
140.60B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
BeOne Medicines | 11,000 |
Hansoh Pharmaceutical Group Company | 8,989 |
JD Health International | 3,564 |
WuXi Biologics | 12,575 |
Akeso | 3,035 |
Sino Biopharmaceutical | 24,379 |
CSPC Pharmaceutical Group | 21,400 |
Sichuan Kelun-Biotech Biopharmaceutical | 1,837 |
Innovent Biologics News
- 10 days ago - Novo Nordisk, Eli Lilly face first major obesity drug rival in China as Innovent gains approval for mazdutide - Seeking Alpha
- 10 days ago - Innovent Biologics Showcases "Dual Innovations" at Oncology R&D Day, Pioneering the Future of Cancer Treatment with Next-Generation IO and ADC Platforms - PRNewsWire
- 13 days ago - Innovent Announces Mazdutide, First Dual GCG/GLP-1 Receptor Agonist, Received Approval from China's NMPA for Chronic Weight Management - PRNewsWire
- 16 days ago - Innovent announces the Phase 3 Clinical Study DREAMS-1 of Mazdutide in China were Orally Presented at ADA 85th Scientific Sessions - PRNewsWire
- 17 days ago - Neutral On Innovent Biologics: Hard To Justify Its Premium - Seeking Alpha
- 18 days ago - Multiple Research Results from Innovent's General Biomedicine Pipeline to be Showcased at the ADA 85th Scientific Sessions - PRNewsWire
- 24 days ago - Innovent Announces Completion of First Participant Dosed in the Seventh Phase 3 Clinical Trial (GLORY-OSA) of Mazdutide in China - PRNewsWire
- 27 days ago - Innovent to Present Multiple R&D Results of General Biomedicine Pipeline at the ADA's 85th Scientific Sessions - PRNewsWire